Earnings ·
Revelation Biosciences reported a net loss of $3.3 million ($0.87 per share) for the three months ended June 30, 2026…
REVBRevelation Biosciences, Inc.
Revelation Biosciences reported a net loss of $3.3 million ($0.87 per share) for the three months ended June 30, 2026, compared to a net loss of $2.4 million in the prior year period. For the six-month period, the company recorded a net loss of $6.3 million ($3.41 per share), up from $4.5 million in 2025. Cash and cash equivalents increased to $11.5 million as of June 30, 2026, from $10.7 million at year-end 2025, primarily due to proceeds from a January 2026 warrant inducement. The company stated that its current liquidity is sufficient to fund operations through the first quarter of 2027. Clinical development continues with Phase 2/3 startup activities for Gemini in acute kidney injury patients, targeting enrollment by year-end. Revelation Biosciences is a clinical-stage life sciences company developing innovative inflammation-based treatments.